Company Filing History:
1 out of 7 
1 out of 12 Years Active: 2024
Title: The Innovative Works of Eunjin Lee: Pioneering Antibody-Drug Conjugates
Introduction: Eunjin Lee, an accomplished inventor based in Daejeon, South Korea, has made significant strides in the field of biopharmaceuticals. With an impressive patent portfolio, Eunjin's work focuses on the development of antibody-drug conjugates (ADCs), showcasing the potential of targeted therapies in treating various diseases.
Latest Patents: Eunjin Lee holds a notable patent titled "Antibody-drug conjugates comprising anti-B7-H3 antibodies." This patent pertains to ADCs where one or more active agents are conjugated to an anti-B7-H3 antibody through a linker. The innovation includes a linker that covalently connects active agents to the antibody, as well as the development of monoclonal antibodies and antigen-binding fragments that specifically target B7-H3. This groundbreaking work includes methods for creating and utilizing these antibodies in therapeutic, diagnostic, and prophylactic applications.
Career Highlights: Over his career, Eunjin Lee has contributed to advancements in biopharmaceutical technology through his work at prominent companies such as Intocell, Inc. and Y-Biologics, Inc. His innovative mindset has driven research and development initiatives aimed at enhancing the efficacy of targeted therapies.
Collaborations: Eunjin has worked alongside esteemed colleagues, including Taekyo Park and Sunyoung Kim. Their collaborative efforts have played a crucial role in advancing the understanding and application of ADCs, further propelling the development of novel therapeutics.
Conclusion: Eunjin Lee exemplifies the spirit of innovation in the biopharmaceutical industry, with his pioneering research on antibody-drug conjugates showing great promise for future medical applications. As the landscape of targeted therapies continues to evolve, Eunjin's contributions remain pivotal in improving treatment outcomes for patients around the world.